Accurate and precise nuclear decay data are fundamental for the use of medical radionuclides in diverse applications in nuclear medicine, namely for the diagnosis and treatment of cancer. This includes the radionuclide half-life, decay branching ratios and gamma-ray and particulate emission intensities and energies, which are critical data to determine the activity, quantitative imaging, quality control and dosimetry assessment to release and use radiopharmaceutical products in a clinical onset.
At the start of the project in May 2021, the PRISMAP catalogue contained eighteen available radionuclides at (Sc-44, Sc-47, Cu-64, Cu-67, Ag-111, La-135, Tb-149, Tb-152, Tb-155, Tb-161, Er-165, Ho-166, Er-169, Yb-175, Pt-195m, Bi-213, At-211 and Ac-225), and this number increased to more than twenty five until the present date. For most of these radionuclides, nuclear decay data were already available but in many cases were determined many decades ago. Avoiding possible biased information, this portaI provides updated nuclear decay data for innovative medical radionuclides, obtained by PRISMAP partners using the current state-of-the-art techniques or from other sources outside the project.
This report provides a review of the status of the nuclear decay data of the diagnostic or therapeutic radionuclides in the PRISMAP catalogue available at the start of the project in May 2021. It includes a summary of the current state of nuclear decay data of these initially available radionuclides using the latest evaluations published by the Nuclear Data Sheets or the Decay Data Evaluation Project.
Nndc website (USA) www.nndc.bnl.gov
IAEA Website: www-nds.iaea.org
Laboratoire National Henri Becquerel Website www.lnhb.fr/en